• Services
    • Equity Reports (Analyst-Ready)
    • Visibility Upgrades (Quartely + As needed)
    • Investor Mapping
  • Press
  • Contact
  • English
    • Deutsch (German)
    • 日本語 (Japanese)
    • Services
      • Equity Reports (Analyst-Ready)
      • Visibility Upgrades (Quartely + As needed)
      • Investor Mapping
    • Press
    • Contact
    • English
      • Deutsch (German)
      • 日本語 (Japanese)
  • info@vasro.net
  • +49 (0)69 90 28 39 81
  • Call us Mon - Fri: 8:30 AM - 6:00 PM
VASRO GmbH
VASRO GmbH
  • Services
    • Equity Reports (Analyst-Ready)
    • Visibility Upgrades (Quartely + As needed)
    • Investor Mapping
  • Press
  • Contact
  • English
    • Deutsch (German)
    • 日本語 (Japanese)

Equity Analysis

VASRO GmbH > Press > Equity Analysis
VASRO GmbH

Investment Strategies: Equity Report Analysis Across Key Industries for 2025

  • May 28, 2025
  • Unkategorisiert
Discover investment strategies for 2025 with equity analysis across technology, financials, green energy, and emerging markets to optimize your portfolio.
Continue Reading
VASRO GmbH

Comprehensive Equity Analysis: Diversified Sector Trends and Forecasts

  • May 27, 2025
  • Energy, Commodity, Real Estate, Pharma & Biotech, Tech
Analyze equity markets with insights on sector trends, macroeconomic factors, and forecasts to optimize portfolio diversification and investment strategies.
Continue Reading
VASRO GmbH

Galaxy Digital achieves Nasdaq listing, marking a new era in growth strategy

  • May 22, 2025
  • Unkategorisiert
Galaxy Digital's Nasdaq listing boosts its U.S. visibility, attracting investors and solidifying its growth strategy in cryptocurrency and artificial intelligence.
Continue Reading
VASRO GmbH

Why Global Investors Are Turning to Asia in 2025

  • May 21, 2025
  • Unkategorisiert
Global investors are drawn to Asia in 2025 due to its economic growth, expanding consumer markets, and opportunities in technology, sustainability, and trade.
Continue Reading
VASRO GmbH

Charles River Laboratories Experiences Significant Stock Surge

  • May 20, 2025
  • Pharma & Biotech
Charles River Laboratories' stock surge reflects strong financial results, governance changes, and strategic growth initiatives, boosting investor confidence.
Continue Reading
VASRO GmbH

Energy Innovations Driving Strategic Industry Trends in 2025

  • May 15, 2025
  • Energy
Energy innovations in 2025 are driving industry trends, boosting sustainability, efficiency, and growth through renewables, storage, and green hydrogen.
Continue Reading
VASRO GmbH

How Equity Analysis Enhances Tech Stock Valuation

  • May 14, 2025
  • Tech
Equity analysis bridges market trends and intrinsic value, offering data-driven insights to accurately value tech stocks and navigate market volatility.
Continue Reading
VASRO GmbH

Block Inc. stock tumbles amid fintech sector struggles

  • May 9, 2025
  • Tech
Block Inc. stock drop of 20% reflects fintech struggles, driven by weak Q1 earnings, stagnant Cash App growth, and reduced full-year guidance.
Continue Reading
VASRO GmbH

Top European Dividend Stocks to Watch for Maximum Returns in 2025

  • May 8, 2025
  • Energy, Commodity, Real Estate, Pharma & Biotech, Tech
Discover top European dividend stocks to watch in 2025, including undervalued gems offering high yields and stability for income-focused investors.
Continue Reading
VASRO GmbH

5 Top Pharma Stocks to Watch for Strong Growth in 2025

  • May 2, 2025
  • Pharma & Biotech
Discover the 5 top pharma stocks to watch in 2025. Gain equity analysis insights on Eli Lilly, J&J, Merck, Thermo-Fisher, and AbbVie for strong growth.
Continue Reading

Posts pagination

Previous 1 2 3 Next

Search

Categories

  • Energy
  • Equity Analysis reports
  • Equity Research Coverage
  • Market Intelligence
  • Pharma & Biotech
  • Tech
  • Unkategorisiert

Recent Posts

Ainos, Inc.: Three Patents Approved in Japan, and a Dataset Gathering Pace September 11, 2026
Baladna: The Capital Is Raised, Algeria Is Building – VASRO Reiterates BUY at QAR 2.33 September 7, 2026
Sirnaomics Ltd.: Every Approved siRNA Drug Works in the Liver. This One Was Injected Into Skin Cancer. VASRO Initiates Coverage With BUY September 7, 2026
Zaptec ASA: Europe’s Largest AC Charging Brand, With the Service Layer Priced at Zero – VASRO Initiates Coverage With BUY August 31, 2026
Spinneys 1961 Holding PLC: The Estate Grew 17%, Demand Did Not — First Half 2026 Update August 12, 2026
VASRO GmbH
VASRO GmbH specializes in equity analysis, market intelligence, and investment strategy for the pharmaceutical, biotechnology, and IT sectors. We deliver tailored insights to drive informed investment decisions and achieve exceptional results.

Discover More

Contact Info

  • Am Hauptbahnhof 16, 60329 Frankfurt am Main, Germany
  • +49 (0)69 90 28 39 81
  • Info@vasro.net
  • 8:30 AM - 6:00 PM

Navigation

  • Imprint
  • Privacy Policy
  • Change privacy settings
  • Application
  • About
  • FAQ

©copyright 2025 VASRO GmbH.